Division of Penn Pain Medicine, Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, Pennsylvania 19146, USA.
Pain Med. 2010 Jun;11(6):847-52. doi: 10.1111/j.1526-4637.2010.00860.x. Epub 2010 Apr 29.
Intrathecal sufentanil is a minimally utilized opioid for patients with intractable pain refractory to traditional intrathecal medications. We present an 86-year-old female with a history of multiple spine surgeries who eventually progressed to having chronic, intractable, and diffuse low back pain. After failing medical management, she underwent a successful intrathecal trial of opioid therapy and was subsequently treated with an implantable drug delivery system (IDDS) or intrathecal pump. We describe the first reported case of formation of a catheter tip granuloma associated with intrathecal infusion of sufentanil. Due to increasing opioid requirements and gradually escalating pain, a computed tomography myelogram was performed to explore neuraxial etiologies of her symptoms. This investigation revealed the presence of a catheter tip-associated inflammatory mass (granuloma). All patients receiving intrathecal medications, including sufentanil, must be considered for the possibility of catheter-associated granuloma, particularly with symptoms of altered neurological function and/or increasing medication requirements associated with worsening pain.
鞘内舒芬太尼是一种在顽固性疼痛患者中应用较少的阿片类药物,这些患者对传统鞘内药物难治。我们介绍了一位 86 岁女性患者,她有多次脊柱手术史,最终发展为慢性、顽固性、弥漫性腰痛。在药物治疗失败后,她接受了鞘内阿片类药物治疗试验,并随后接受了植入式药物输送系统(IDDS)或鞘内泵治疗。我们描述了首例鞘内输注舒芬太尼引起的导管尖端肉芽肿的病例报告。由于阿片类药物需求不断增加且疼痛逐渐加剧,进行了计算机断层脊髓造影术以探讨其症状的中枢神经系统病因。该检查显示存在与导管尖端相关的炎症性肿块(肉芽肿)。所有接受鞘内药物治疗的患者,包括舒芬太尼,都必须考虑存在与导管相关的肉芽肿的可能性,尤其是在出现改变神经功能的症状和/或与疼痛加重相关的药物需求增加的情况下。